

DAFTAR PUSTAKA

1. Suci LN. Pendekatan Diagnosis dan Tata Laksana Pneumonia pada Anak. *J Kedokt Nanggroe Med.* 2020;3(1):30–8.
2. Torres A, Niederman MS, Chastre J, Ewig S, Fernandez-Vandellos P, Hanberger H, et al. International ERS/ESICM/ESCMID/ALAT Guidelines for The Management of Hospital-acquired Pneumonia and Ventilator-associated Pneumonia. *Eur Respir J.* 2017;50(3).
3. Metrics GH. Global burden of 369 Diseases and Injuries in 204 Countries and Territories , 1990 – 2019 : A Systematic Analysis for the Global Burden of Disease Study 2019. 2020;396.
4. Cilloniz C, Martin-loeches I, Garcia-vidal C, Jose AS, Torres A. Microbial Etiology of Pneumonia : Epidemiology , Diagnosis and Resistance Patterns. *Int J Mol Sci.* 2016;17(2120):1–18.
5. Kemenkes RI. Survei Kesehatan Indonesia (SKI) Tahun 2023. In 2023.
6. Dinkes Padang. Laporan Tahunan Tahun 2019 edisi 2020. 2020.
7. Wathan UN, Nahdlatul U, Mataram W. Tingkat Pengetahuan Masyarakat terhadap Penggunaan Antibiotik (Amoxicilin) Berdasarkan Usia Di Dusun Karang Panasan Kabupaten Lombok Utara. *J Keperawatan.* 2019;54–62.
8. Wells BG, DiPiro JT, Schwinghammer, T. L. & DiPiro C V. *Pharmacotherapy Handbook Ninth Edition.* McGraw-Hill Education; 2015.
9. Negara KS. Analisis Implementasi Kebijakan Penggunaan Antibiotika Rasional Untuk Mencegah Resistensi Antibiotika di RSUP Sanglah Denpasar: Studi Kasus Infeksi Methicillin Resistant Staphylococcus Aureus. *J Adm Kebijak Kesehat.* 2014;1(1):42–50.
10. CDC. Antibiotic / Antimicrobial Resistance CDC [Internet]. 2025. p. 0–2. Available from: <https://www.cdc.gov/antimicrobial-resistance/about/index.html>
11. Gracia JE, Serrano RB, Garrido JF. Medication Errors and Drug Knowledge Gaps Among Critical-care Nurses : A Mixed Multi-method Study. *BMC Health Serv Res.* 2019;19(640):1–9.
12. Kuti EL, Patel AA, Coleman CI. Impact of inappropriate antibiotic therapy

- on mortality in patients with ventilator-associated pneumonia and blood stream infection: A meta-analysis. *J Crit Care*. 2008 Mar;23(1):91–100.
13. PDPI. Panduan Umum Praktik Klinis Penyakit Paru dan Pernapasan. Perhimpunan Dokter Paru Indonesia. 2021.
 14. Cohen F, Chiche L, Rebaudet S, Pegliasco H, Brunel V. Incidental Pneumonia on PET Imaging. *La Rev Med Interne*. 2021;42(3):225–6.
 15. Kemenkes RI. Profil Kesehatan Indonesia Tahun 2018. 2018.
 16. Palupi R, Kameliawati F, G AA, Hidayah AQ, Ikhsan M, Umami R. Implementasi Terapi Non Farmakologi dengan Masalah Pneumonia. *NEM*; 2023.
 17. Shankar PR, Alshakka MA. *Clinical Pharmacy and Therapeutics Sixth Edition*. Elsevier; 2019.
 18. Lim WS. Pneumonia—Overview. *Encycl Respir Med Second Ed*. 2021;4:185–97.
 19. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America / American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. *CID*. 2007;44(Suppl 2).
 20. Az Zahra GN, Pardilawati CY, Junando M, Oktoba Z. Article Review: Faktor-Faktor yang Berhubungan Dengan Kejadian VAP (Ventilator-Associated Pneumonia) pada Pasien ICU yang Menggunakan Ventilator Mekanik. *J Farm SYIFA*. 2025;3(1):43–9.
 21. Affanin RN, Victoria AZ, Nuraeni A. Hubungan Lama Penggunaan dan Frekuensi Oral Hygiene Pasien dengan Ventilator Mekanik terhadap Ventilator-Associated Pneumonia (VAP) di Ruang ICU. *Pena Nurs*. 2022;1(1):13–21.
 22. Almirall J, Serra-prat M. Risk Factors for Community-Acquired Pneumonia in Adults: A Systematic Review of Observational Studies. *Respiration*. 2017;1–13.
 23. Bhardwaj VJ, Rishik V, Gizem Y, Abhishek. *StatPearls*. 2023. Pneumonia Pathology. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK526116/>

24. Rosdiana D, Siregar FM, Ediwi NC, Putri RT, Er Z. Mortality and Associated Factors Among Community-acquired Pneumonia Patients: A Cross-sectional Study in a Provincial Referral Hospital in Indonesia. *Narra j.* 2025;5(2):1–12.
25. Kemenkes RI. Pedoman Nasional Pelayanan Kedokteran (PNPK). 2023;1–65.
26. Hidayat FA. Telaah Penggunaan Antibiotik pada Pasien Pneumonia Komunitas Di RSUP Dr. M. Djamil Padang dengan Menggunakan Metode Gyssens. Universitas Andalas; 2024.
27. FDA. Hospital-Acquired Bacterial Pneumonia and Ventilator- Associated Bacterial Pneumonia : Developing Drugs for Treatment Guidance for Industry Hospital-Acquired Bacterial Pneumonia and Ventilator- Associated Bacterial Pneumonia : Developing Drugs for Treatme. 2020. 1–17 p.
28. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. American Thoracic Society Diagnosis and Treatment of Adults with Community-acquired Pneumonia An Of fi cial Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. *Am J Respir Crit Care Med.* 2019;200(7):1–23.
29. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis.* 2016;63(5):61–111.
30. Pangalila FJV, Soepandi PZ. Pedoman Antibiotik Empirik di Unit Rawat Intensif. 2019. 16–21 p.
31. Başıyigit S. Clinical Pulmonary Infection Score (CPIS) as A Screening Tool in Ventilatory Associated Pneumonia (VAP). *Med Bull Sisli Hosp.* 2017;51(2):133–41.
32. Kharisma D. Telaah Rasionalitas Penggunaan Antibiotik pada Pasien Pneumonia Komunitas di Rumah Sakit Universitas Andalas Padang pada Tahun 2023. Universitas Andalas; 2024.
33. Wulandari S, Komala Sari D, Handayani D, Pertiwi R, Rahmawati R, Yona

- Harianti Putri. Pencegahan Resistensi Melalui Sosialisasi Bijak Menggunakan Antibiotik Pada Masyarakat di Kawasan Wisata Pantai Panjang. *J Community Empower*. 2023;1(1):1–5.
34. Muntasir, Muntasir, Priska Ernestina Tenda, Andi Ifriany Harum MP. Antibiotik dan Resistensi Antibiotik. Paper Knowledge. Rizmedia Pustaka Indonesia. 2021. 1–48 p.
 35. Etebu E, Ibemologi Ariekpar. Classification and Mechanisms of Action with Emphasis on Molecular Perspectives Ebimieowei. *Int J Appl Microbiol Biotechnol Res*. 2016;4(2016):90–101.
 36. Anggita D, Nurisyah S, Wiriansya EP. Mekanisme Kerja Antibiotik. *UMI Med J*. 2022;7(1):46–58.
 37. Kristiningrum S, Widyawati IY, Huda N. Identifikasi Infeksi Multidrug Resistant Organism (MDRO) pada Pasien ICU. *J Telenursing*. 2023;5(1):180–9.
 38. Lia Yunita S, Novia Atmadani R, Titani M. Faktor-faktor yang Mempengaruhi Pengetahuan dan Perilaku Penggunaan Antibiotika Pada Mahasiswa Farmasi UMM. *Pharm J Indones*. 2021;6(2):119–23.
 39. Khasanah R., Puspitasari K, Nuryastuti T, Yuniarti N. Prevalensi Multidrug-Resistant *Klebsiella pneumoniae* dan Evaluasi Kesesuaian Antibiotik Empiris Berdasarkan Nilai Prediksi Farmakokinetik Terhadap Outcome Klinis di RSUP Dr. Soeradji Tirtonegoro Klaten. *Maj Farm*. 2019;16(1):27–33.
 40. Estiningsih D, Puspitasari I, Nuryastuti T. Identifikasi Infeksi Multidrug-Resistant Organisms (MDRO) pada Pasien yang Dirawat di Bangsal Neonatal Intensive Care Unit (NICU) RSUP DR. Soeradji Tirtonegoro Klaten. *J Manaj dan Pelayanan Farm*. 2016;6(3):243–8.
 41. Rastiti NP, Garnis Dolesgit NM, Yunita Kartika Dewi NN. Case Study on Nurse Care for Covid-19 Patients with MDRO (Multiple Drug Resistent Organism) in Isolation Intensive Care Unit, Bali Mandara Hospital. *Nurs Heal Sci J*. 2022;2(3):261–5.
 42. Chamekh M. Differential Susceptibility to infectious Respiratory Diseases between Males and Females Linked to Sex-Specific innate immune inflammatory Response. 2017;8(1806):1–7.

43. Megumi Aomatsu, Takayuki Kato, Emiko Kasahara SK. Gender difference in tumor necrosis factor- α production in human neutrophils stimulated by lipopolysaccharide and interferon- γ . *Biochem Biophys Res Commun*. 2013;441(1):220–5.
44. Strzelak A. Tobacco Smoke Induces and Alters Immune Responses in the Lung Triggering Inflammation , Allergy , Asthma and Other Lung Diseases : A Mechanistic Review. 2018;
45. Darmojo B. Buku Ajar Boedhi-Darmojo Geriatri: Ilmu Kesehatan Usia Lanjut Edisi Ke-6. 6th ed. Jakarta; 2020. 1–913 p.
46. Kuhlmann E, Kovacs EJ. The Aging Lung. 2013;8:1489–96.
47. Almirall J, Serra-Prat M, Bolibar I. Risk factors for community-acquired pneumonia in adults : Recommendations for its prevention. *Cajournal*. 2015;2(2):32–7.
48. Aldaz P, Vargas DA, Mascarós E, Redondo E. Incidence and risk factor prevalence of community-acquired pneumonia in adults in primary care in Spain (NEUMO-ES-RISK project). *BMC Infect Dis* [Internet]. 2016;1–8. Available from: <http://dx.doi.org/10.1186/s12879-016-1974-4>
49. Andres AL, Albaladejo- R, Miguel- J De, Barrera VH, Ji Z, Zamorano- JJ, et al. Incidence and Outcomes of Hospitalization for Community-acquired, Ventilator-associated, and Non-ventilator Acquired Pneumonias in Patients with Type 2 Diabetes Mellitus in Spain. *BMJ Open Diab Res Care*. 2020;8(1):1–11.
50. Molly P, Susanto H, Nugraha DP, Chung UM, Chung UM, Chung UM. Evaluasi Penggunaan Antibiotik pada Pasien ICU (Intensive Care Unit) Di Rumah Sakit Mitra Sehat dengan Metode DDD (Defined Daily Dose) Dan Gyssens. *Sainsbertek J Ilm Sains Teknol*. 2023;1–8.
51. Komite Farmasi dan Terapi Rumah Sakit Universitas Andalas. Formularium Rumah Sakit Universitas Andalas 2024. 2024. 1–103 p.
52. VPI Pharmaceutical. VPI-AMIKACIN: Amikasin Sulfate Injection, USP. 2020.
53. Hospira. Ampicillin and Sulbactam for Injection, USP. 2025;1–16.
54. Hikma Canada. Cefepime For Injection USP. 2022;1–38.

55. Pfizer. Sulbactam Sodium/Cefoperazone Sodium. 2023;1–15.
56. Novaplus. Ceftriaxone for Injection, USP. 2022;
57. Hospira. Tazicef Brand of Ceftazidime for Injection, USP. 2020;1–16.
58. Pfizer. Ciprofloxacin Injection USP. 2019;1–57.
59. Meitheal. Contepo (Fosfomycin) for Injection. 2025;1–16.
60. Fresenius Kabi. Imipenem and Cilastatin for Injection, USP. 2022;
61. Hospira. USPI-Levofloxacin Injection. 2019;1–48.
62. Pfizer. Meropenem for Injection USP. 2018;1–38.
63. FDA. Moxifloxacin Injection, for Intravenous Use. 2020;1–52.
64. Korczak L, Majewski P, Iwaniuk D, Sacha P, Matulewicz M, Wieczorek P, et al. Molecular Mechanisms of Tigecycline-resistance Among Enterobacterales. *Front Cell Infect Microbiol.* 2024;1–14.
65. FDA. Tygacil (Tigecycline) for Injection. 2025;1–29.
66. Novaplus. Vancomycin Hydrochloride for Injection , USP. 2021;1–12.
67. Dimopoulou D, Moschopoulos CD, Dimopoulou K, Dimopoulou A, Berikopoulou MM, Andrianakis I, et al. Duration of Antimicrobial Treatment in Adult Patients with Pneumonia : A Narrative Review. *MDPI.* 2024;13(1078):1–26.
68. Nasrul E. Artikel Penelitian Pola Kuman dan Uji Kepekaan pada Pasien Community Acquired Pneumonia di RSUP Dr . M . Djamil Padang Tahun. 2016;8(3):553–7.
69. Interna Publishing. Ilmu Penyakit Dalam Edisi Vi. Infeksi Nosokomial. 2014.
70. Handayani R, Hamidie R. Profil Bakteri dan Pola Sensitivitas Antibiotik pada Pasien Pneumonia Terkait Ventilator di Rumah Sakit Tersier ICU di Jawa Barat , Indonesia aeruginosa , Escherichia coli , Klebsiella pneumoniae , dan Acinetobacter , serta bakteri Gram-positif. 2025;3(2):203–10.
71. Diriba K, Kassa T, Alemu Y, Bekele S. In Vitro Biofilm Formation and Antibiotic Susceptibility Patterns of Bacteria from Suspected External Eye Infected Patients Attending Ophthalmology Clinic , Southwest Ethiopia. 2020;
72. Mustikaningtyas MH, Semedi BP. Bacterial and Sensitivity Pattern of

Pathogens Causing Ventilator-Associated Pneumonia in Intensive Care Unit. MBIOMJ. 2022;32(1):22–8.

73. Walden AP, Clarke GM, McKechnie S, Hutton P, Gordon AC, Rello J, et al. Patients with Community Acquired Pneumonia Admitted to European Intensive Care Units : An Epidemiological Survey of the GenOSept Cohort. Crit Care. 2014;18(2):1–9.
74. Laxminarayan R, Duse A, Wattal C, Zaidi AKM, Wertheim HFL, Sumpradit N, et al. Antibiotic Resistance-the Need for Global Solutions. 2013;1–42.

